Aska Pharmaceutical Co., Ltd.

Atsushi Shinbo

Hideo Kobayashi

Youichi Nakano

Makoto Okada

Kotaro Gotanda

Shuichiro Sato

Kenji Kawade

Akira Asagarasu

Junichi Watanabe

Yuta Ito

Provided is a urination disorder-improving agent useful for treating or improving (or alleviating) a urination disorder regardless of the degree or presence of prostatomegaly. The urination disorder-improving agent contains a 2-oxapregnane compound represented by the following formula (1) as an active ingredient. (In the formula, Rto Rrepresent an alkyl group such as methyl group, Rrepresents an alkylcarbonyl group such as acetyl group, X represents a halogen atom such as a chlorine atom, Y represents a hydroxyl group or oxo group bonded to the 11-position, 15-position, or 16-position of the steroid skeleton.)

Urination disorder-improving agent

The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula,

Substituted pyrrolo[1,2-a]quinoxalines as PDE9 inhibitors

Substituted imidazo[1,5-A]quinoxalines as phosphodiesterase 9 inhibitors

This invention provides thienopyrimidine derivatives of the formula, 

Thienopyrimidine derivatives

Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor

Growing community of inventors

Niiza, Japan

Atsushi Shinbo